



Press release

Management change at Dr. Falk Pharma GmbH

Freiburg, April 6, 2023

Kai Pinkernell takes over as Managing Director Science & Innovation. He succeeds Roland Greinwald, who is retiring after 30 years with the company.

With effect from April 1, 2023, Kai Pinkernell, MD, took over as Managing Director Science & Innovation of Dr. Falk Pharma GmbH in Freiburg, Germany. He succeeded Roland Greinwald, Ph.D., who retired after 30 years with the company at the end of March 2023. Kai Pinkernell will be managing Dr. Falk Pharma GmbH together with Philipp Argast, Managing Director Finance & Administration and Torben Zachmann, Managing Director Commercial.

“I remember very clearly learning at medical school how to treat inflammatory bowel disease with Dr. Falk Pharma products. This is why it is a particular pleasure for me to be given the opportunity to contribute to your company’s great international success. I look forward to working with all of you to drive ongoing projects and further advance Dr. Falk Pharma’s innovative power,” Kai Pinkernell told the staff. Kai Pinkernell has spent many years working in pharmaceutical research both in Germany and abroad, and has longstanding experience in clinical research and innovative therapeutic approaches.

Dr. Falk Pharma GmbH, expert in digestive and metabolic medicine, started repositioning itself at the beginning of the year. The clear focus on innovative products for gastroenterology and hepatology means that Science & Innovation will be strengthened. “We are delighted that Kai Pinkernell will be joining us. His international expertise in preclinical and clinical research will provide the momentum that will be essential for the expansion of our product portfolio. We have a lot of projects in our pipeline, in particular in the areas of inflammatory bowel disease, celiac disease, gastroparesis and liver disease. To support our growing international business, we are also planning to expand and strengthen in- and out-licensing, as well as our partnering activities. This is why we are particularly excited to have Kai Pinkernell on board,” says Martin Falk, Ph.D., shareholder of Dr. Falk Pharma GmbH.

Roland Greinwald had been at the helm of the product innovation division for the family business since the year 2000. Having joined the company as Project Manager for Clinical Research on April 1, 1993, he became Head of Research & Development seven years later, and joined Dr. Falk Pharma’s management in 2018. “Roland Greinwald motivated our colleagues around the world and made a key contribution to our company’s success through his roles in research and development. We would like to express our boundless and heartfelt gratitude for his outstanding work and his unwavering commitment to the company. We wish him nothing but the very best for this new phase in his life, the best of health and would like to say, from the bottom of our hearts: THANK YOU,” said Carola Falk, shareholder of Dr. Falk Pharma GmbH at Roland Greinwald’s farewell celebration.



Press release

Digital photographs in print-ready resolution are available to illustrate this press release. They may only be used for editorial purposes. Use is free of charge when credit is given as "Photo: Dr. Falk Pharma GmbH". Graphic editing – except for cropping out the main motif – is prohibited.



Kai Pinkernell, Ph.D., new Managing Director Science & Innovation at Dr. Falk Pharma GmbH.

The new management of Dr. Falk Pharma GmbH: Torben Zachmann, Managing Director Commercial (back, left), Philipp Argast, Managing Director Finance & Administration (back, right), and Kai Pinkernell, MD, Managing Director Science & Innovation (front, right). After 30 years with the company, Roland Greinwald, Ph.D., (front, left), retired as Managing Director Science & Innovation.

About Dr. Falk Pharma GmbH

Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, the company brings together physicians, scientists, and patients to devise new and powerful approaches to patient care. Dr. Falk Pharma engages in pre-clinical and clinical stage research that aims to meaningfully improve therapeutic practice as well as patient health and well-being. A family-owned business with a global presence, Dr. Falk Pharma has ten affiliates in Europe and Australia and is continuously growing. The company has its headquarters and R&D facilities in Freiburg, Germany, its pharmaceutical products are manufactured in Europe, mainly at sites in Germany, France, Italy and Switzerland. Dr. Falk Pharma GmbH employs approximately 1000 individuals globally and 216 in Freiburg.

Further information on Dr. Falk Pharma can be found online: <https://drfalkpharma.com>

Contact

Dr. Falk Pharma GmbH

Babette Kopp
Corporate Communications
Leinenweberstr. 5
79108 Freiburg
Germany
Phone: +49 761 1514-0
Email: babette.kopp@drfalkpharma.de
www.drfalkpharma.de